Journal
DRUG DISCOVERY TODAY
Volume 11, Issue 19-20, Pages 931-938Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2006.08.004
Keywords
-
Categories
Ask authors/readers for more resources
Alzheimer's disease (AD) is the most common form of senile dementia and the fourth highest cause of disability and death in the elderly. Amyloid-beta (A beta) has been widely implicated in the etiology of AD. Several mechanisms have been proposed for A beta clearance, including receptor-mediated A beta transport across the blood-brain barrier and enzyme-mediated A beta degradation. Moreover, pre-existing immune responses to A beta might also be involved in A beta clearance. In AD, such mechanisms appear to have become impaired. Recently, therapeutic approaches for A beta clearance, targeting immunotherapy and molecules binding A beta, have been developed. In this review, we discuss recent progress and problems with respect to A beta clearance mechanisms and propose strategies for the development of therapeutics targeting A beta clearance.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available